Charles Schwab’s ENDRA Life Sciences NDRA Stock Holding History

Charles Schwab’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	-$47K	–	3497
2021 Q1	$47K	Buy	+1	New	+$74.9K	﹤0.01%	3442

Other funds holding NDRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

55I LLC Boston, Massachusetts $3.58B AUM 17.97% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Charles Schwab's NDRA Position: Q2 2021 in Review

Charles Schwab sold out of ENDRA Life Sciences (NDRA) in Q2 2021, closing a stake of 1 share — an estimated $47K sold.

Charles Schwab first reported a position in NDRA in Q1 2021 and held it in 1 quarter. The position peaked at $47K in Q1 2021. 14 funds tracked by Wall St. Rank hold NDRA as of Q2 2021.

Charles Schwab reported no remaining ENDRA Life Sciences position as of Q2 2021 after selling out during the quarter.
Charles Schwab sold 1 ENDRA Life Sciences share in Q2 2021, an estimated $47K.
Charles Schwab first reported a position in ENDRA Life Sciences in Q1 2021 and held it in 1 quarter.
Charles Schwab's ENDRA Life Sciences position peaked at $47K in Q1 2021.
14 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.